Year archive

Ascentage Pharma Group International — 2024 filings

All 50 regulatory filings released by Ascentage Pharma Group International (6855) in 2024, sourced directly from the official regulator.

50 Filings

2024 Period

2024 filings (50)

Filing	Released	Lang
INSIDE INFORMATION AND OVERSEAS REGULATORY ANNOUNCEMENT - UPDATES ON PROPOSED INITIAL PUBLIC OFFERING Capital/Financing Update	2024-12-29	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024 Regulatory Filings	2024-12-04	English
Voluntary Announcement - New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List Regulatory Filings	2024-11-28	English
List of directors and their roles and functions Board/Management Information	2024-11-25	English
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS Board/Management Information	2024-11-25	English
Voluntary Announcement - Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China's NMPA Regulatory Filings	2024-11-17	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024 Regulatory Filings	2024-11-06	English
Voluntary Announcement - Ascentage Pharma to Present Results from Multiple Clinical Studies of olverembatinib, lisaftoclax, APG-5918 and APG-2449 at the 2024 American Society of Hematology (ASH) Annu Regulatory Filings	2024-11-06	English
SUPPLEMENTAL ANNOUNCEMENT - (1) CANCELLATION OF THE ORIGINAL GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND (2) REALLOCATION OF UNDERLYING SHARES OF THE ORIGINAL GRANT OF Capital/Financing Update	2024-10-25	English
Ascentage Pharma Received CDE Clearance for Registrational Phase III Studies of APG-2449 for Treatment of Patients with NSCLC Regulatory Filings	2024-10-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024 Regulatory Filings	2024-10-04	English
INTERIM REPORT 2024 Interim / Quarterly Report H1 2024	2024-10-01	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024 Regulatory Filings	2024-09-04	English
FURTHER GRANT OF AWARDS UNDER THE 2018 RSU SCHEME, THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME Regulatory Filings	2024-09-02	English
ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 Interim / Quarterly Report H1 2024	2024-08-22	English
NOTICE OF BOARD MEETING Regulatory Filings	2024-08-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024 Regulatory Filings	2024-08-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024 Regulatory Filings	2024-07-04	English
VOLUNTARY ANNOUNCEMENT - OPTION PAYMENT RECEIVED UNDER THE EXCLUSIVE OPTION AGREEMENT WITH TAKEDA Capital/Financing Update	2024-07-04	English
Next Day Disclosure Return Share Issue/Capital Change	2024-06-21	English
CLOSING OF ISSUANCE OF NEW SHARES UNDER GENERAL MANDATE Capital/Financing Update	2024-06-21	English
Voluntary Announcement - Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 European Hematology Association Hybrid Congress (EHA 2024) Regulatory Filings	2024-06-17	English
ISSUANCE OF NEW SHARES UNDER GENERAL MANDATE Capital/Financing Update	2024-06-14	English
INSIDE INFORMATION - ENTRY INTO OF THE EXCLUSIVE OPTION AGREEMENT WITH TAKEDA INTERNATIONAL Regulatory Filings	2024-06-14	English
INSIDE INFORMATION CONFIDENTIAL FILING OF DRAFT REGISTRATION STATEMENT ON FORM F-1 Capital/Financing Update	2024-06-14	English
List of directors and their roles and functions Board/Management Information	2024-06-10	English
(1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES Board/Management Information	2024-06-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024 Regulatory Filings	2024-06-06	English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST RESULTS FROM MULTIPLE CLINICAL STUDIES OF ITS LEAD DRUG CANDIDATES IN 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Regulatory Filings	2024-05-24	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 10, 2024 Declaration of Voting Results & Voting Rights Announcements	2024-05-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024 Share Issue/Capital Change	2024-05-07	English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT FOUR STUDIES, INCLUDING AN ORAL REPORT FEATURING THE LATEST DATA OF OLVEREMBATINIB IN SDH-DEFICIENT GIST Regulatory Filings	2024-04-25	English
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2024-04-15	English
Notification Letter and Request Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications Report Publication Announcement	2024-04-15	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 10, 2024 AGM Information	2024-04-15	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2024-04-15	English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2024-04-15	English
ANNUAL REPORT 2023 Annual Report FY 2023	2024-04-15	English
VOLUNTARY ANNOUNCEMENT - ACQUISITION OF SHARES BY THE CHAIRMAN AND EXECUTIVE DIRECTOR Director's Dealing	2024-04-08	English
VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA PRESENTS RESULTS FROM THREE STUDIES AT 2024 AMERICAN ASSOCIATION OF CANCER RESEARCH ANNUAL MEETING Regulatory Filings	2024-04-08	English
VOLUNTARY ANNOUNCEMENT - ACQUISITION OF SHARES BY DIRECTORS Director's Dealing	2024-04-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024 Regulatory Filings	2024-04-03	English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023 Annual Report FY 2023	2024-03-27	English
NOTICE OF BOARD MEETING Regulatory Filings	2024-03-15	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024 Share Issue/Capital Change	2024-03-06	English
Voluntary Announcement - Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting Regulatory Filings	2024-03-06	English
Voluntary Announcement - Ascentage Pharma Received Clearance from U.S. FDA to Initiate Global Registrational Phase 3 Clinical Trial for Olverembatinib in Previously Treated Patients with Chronic Phas Regulatory Filings	2024-02-14	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024 Share Issue/Capital Change	2024-02-06	English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY THE TRUSTEE FOR THE PURPOSE OF THE 2022 RSU SCHEME Transaction in Own Shares	2024-02-02	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023 Regulatory Filings	2024-01-05	English

Filings by year

2026 26 filings
2025 58 filings
2024 50 filings
2023 49 filings
2022 60 filings
2021 88 filings
2020 57 filings
2019 20 filings